TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36000695

Group type: EXPERIMENTAL
Intervention: LMA Protector
Number of subjects: 154

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 154
Study: 33684116

Group type: EXPERIMENTAL
Intervention: Electronic Data Capture (EDC)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Paper-based Data Capture (PDC)
Number of subjects: 1068
Study: 34038198

Group type: EXPERIMENTAL
Intervention: 0.75% isobaric ropivacaine plus 5 µg sufentanil intrathecally (Group RS)
Number of subjects: 112

Group type: COMPARATOR
Intervention: 0.75% isobaric ropivacaine intrathecally (Group R)
Number of subjects: 112
Study: 33285665

Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block (SAPB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intercostal nerve block (ICNB)
Number of subjects: 50
Study: 36084710

Group type: EXPERIMENTAL
Intervention: EE+DNG
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: EV+DNG
Number of subjects: 59

Group type: COMPARATOR
Intervention: DNG only
Number of subjects: 59
Study: 32062566

Group type: EXPERIMENTAL
Intervention: Real treatment (rTMS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Active Control
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 43
Study: 35342059

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Pharmacological interventions
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 212
Study: 32297259

Group type: EXPERIMENTAL
Intervention: Fast track surgery nursing program
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 84
Study: 35652434

Group type: EXPERIMENTAL
Intervention: Two daily applications of 1 h each
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: A 2-h single application
Number of subjects: 86
Study: 34152699

Group type: EXPERIMENTAL
Intervention: Wiltse approach
Number of subjects: 780

Group type: COMPARATOR
Intervention: Conventional open approach
Number of subjects: 780
Study: 32980290

Group type: EXPERIMENTAL
Intervention: Bempedoic acid (180 mg once daily for 12 to 52 weeks)
Number of subjects: 3621

Group type: COMPARATOR
Intervention: Placebo (once daily for 12 to 52 weeks)
Number of subjects: 3621

Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 3621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3621
Study: 36040329

Group type: EXPERIMENTAL
Intervention: THC 10%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: THC/CBD 9%/9%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All cannabis products
Number of subjects: 12
Study: 33155505

Group type: EXPERIMENTAL
Intervention: Autologous platelet rich fibrin mixed with antibiotics (Colistin, Ciprofloxacin‐Colistin combination, Tobramycin)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Autologous platelet rich fibrin mixed with antibiotics
Number of subjects: 10
Study: 32675314

Group type: EXPERIMENTAL
Intervention: Nasal Continuous Positive Airway Pressure (nCPAP) administered in tertiary centers for term babies for <24 hours
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Conservative management in nontertiary centers
Number of subjects: 1085
Study: 34139357

Group type: EXPERIMENTAL
Intervention: Pelvic floor biofeedback (BIO)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Perianal injection with bulking agents (INJ)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Enhanced medical management (EMM)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Sacral nerve electrical stimulation (SNS)
Number of subjects: 285
Study: 32028397

Group type: EXPERIMENTAL
Intervention: High-low impact exercise program with pelvic floor muscle education and training (n=133)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group (n=127)
Number of subjects: 260
Study: 35683992

Group type: EXPERIMENTAL
Intervention: 15 g/day RMD
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 25 g/day RMD
Number of subjects: 49
Study: 34287784

Group type: EXPERIMENTAL
Intervention: hsa‐miR‐199a‐3p
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: hsa‐miR‐149‐3p
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: hsa‐miR‐149‐5p
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control miR
Number of subjects: 39
Study: 32335305

Group type: COMPARATOR
Intervention: Participants reporting no change in walking difficulty (0-4 Likert scale)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Participants reporting one point improvement in walking ability (0-4 scale)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Participants reporting two point improvement in walking ability (0-4 scale)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Participants reporting one point decline in perceived walking difficulty (0-4 scale)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Participants reporting two point decline in perceived walking difficulty (0-4 scale)
Number of subjects: 777
Study: 35193478

Group type: EXPERIMENTAL
Intervention: 1.2% CAF-MR
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.8% CAF-MR
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2.4% CAF-MR
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (water)-MR
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 34856689

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 39
Study: 34750035

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab (NIVO+IPI) every 3 weeks for four doses followed by Nivolumab monotherapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab (NIVO+IPI)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 108
Study: 35500098

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin (high-dose group)
Number of subjects: 218

Group type: COMPARATOR
Intervention: 20 mg atorvastatin (low-dose group)
Number of subjects: 218
Study: 32034790

Group type: EXPERIMENTAL
Intervention: Phase III trials
Number of subjects: 252

Group type: COMPARATOR
Intervention: Phase II trials
Number of subjects: 252
Study: 35635580

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (endocrine therapy + chemotherapy)
Number of subjects: 18437

Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 18437
Study: 33831632

Group type: EXPERIMENTAL
Intervention: Incentives for medication adherence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34143714

Group type: EXPERIMENTAL
Intervention: Experiential/traditional music therapy (MG group)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Combined treatment with experiential/traditional music and acupuncture (AP/MG group)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard care only (CG group)
Number of subjects: 116
Study: 32432448

Group type: EXPERIMENTAL
Intervention: Game-based training program (GB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Multilateral training approach (MA)
Number of subjects: 40
Study: 36455163

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Operative treatment
Number of subjects: 0
Study: 32705835

Group type: EXPERIMENTAL
Intervention: Hui-puncture method
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 100
Study: 35686999

Group type: EXPERIMENTAL
Intervention: Healthy Change Program (intervention group)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Attention-control sessions (control group)
Number of subjects: 294
Study: 33467421

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) - 30 inspiratory efforts twice daily, 5 days a week, at 50%, 60%, 70%, and 80% of maximum inspiratory pressure (MIP) for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (50% of MIP for 4 weeks)
Number of subjects: 20
Study: 32406771

Group type: EXPERIMENTAL
Intervention: Percutaneous intraductal microwave ablation followed by metallic stenting
Number of subjects: 12
Study: 35978315

Group type: EXPERIMENTAL
Intervention: Ticaloguard® (generic ticagrelor)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Brilique® (brand ticagrelor)
Number of subjects: 29
Study: 32680841

Group type: EXPERIMENTAL
Intervention: CVD prevention programme focusing on promotion of physical activity and healthy lifestyle
Number of subjects: 5761

Group type: COMPARATOR
Intervention: Reference group from the general population in Stockholm County
Number of subjects: 5761
Study: 35212300

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma injection
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lidocaine injection
Number of subjects: 34
Study: 33545749

Group type: EXPERIMENTAL
Intervention: Intravenous infusion
Number of subjects: 65

Group type: COMPARATOR
Intervention: No intravenous infusion (control)
Number of subjects: 65
Study: 34984830

Group type: EXPERIMENTAL
Intervention: Flipped classroom approach
Number of subjects: 94

Group type: COMPARATOR
Intervention: Traditional educational approach (control)
Number of subjects: 94
Study: 32285499

Group type: EXPERIMENTAL
Intervention: Community intervention consisting of 18 sessions with activities including educational workshops, mindfulness, yoga, walking, and visits to urban gardens.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Community intervention
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (nonlonely controls)
Number of subjects: 55
Study: 32665179

Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound-guided TTMPB with 20 mL of 0.25% bupivacaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound-guided TTMPB
Number of subjects: 48
Study: 34255199

Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + sterile saline solution (SSL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + 2% chlorhexidine gel (CHX gel)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 20
Study: 36669426

Group type: EXPERIMENTAL
Intervention: Standard adjuvant radiation therapy (RT) 60Gy/30 fractions over 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerated radiation therapy (6 d a week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of high-risk features (T3-T4 primary tumours with N2-N3 nodes along with ECE)
Number of subjects: 0
Study: 34190016

Group type: EXPERIMENTAL
Intervention: Bedtime hypertension chronotherapy (ingestion of BP-lowering medications at bedtime)
Number of subjects: 23972

Group type: EXPERIMENTAL
Intervention: Bedtime hypertension chronotherapy
Number of subjects: 23972

Group type: COMPARATOR
Intervention: Upon-waking/morning hypertension treatment-time scheme
Number of subjects: 23972
Study: 32659891

Group type: EXPERIMENTAL
Intervention: 30,000 IU cholecalciferol/week for six months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 35259654

Group type: EXPERIMENTAL
Intervention: Weight-based discrimination portrayed as legitimate
Number of subjects: 327

Group type: COMPARATOR
Intervention: Weight-based discrimination portrayed as illegitimate
Number of subjects: 327
Study: 32487024

Group type: EXPERIMENTAL
Intervention: Dementia Friends (a 60‐min interactive class that teaches about dementia and its effects on people's lives)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Education as usual
Number of subjects: 301
Study: 34724874

Group type: EXPERIMENTAL
Intervention: Trial and error (TEL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Error-based learning (EBL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Systematic instruction (SI)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 38
Study: 33244881

Group type: EXPERIMENTAL
Intervention: Percutaneous Catheter Drainage (PCD)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Percutaneous Needle Aspiration (PNA)
Number of subjects: 543
Study: 32221683

Group type: EXPERIMENTAL
Intervention: Endovascular simulator training
Number of subjects: 305

Group type: COMPARATOR
Intervention: Theoretical seminar
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Simulator training (subgroup analysis)
Number of subjects: 305
Study: 36261832

Group type: EXPERIMENTAL
Intervention: Reminder letters about CVD risk
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Reminder letters about CVD risk with Cochrane blogshots
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (received a letter about their CVD risk)
Number of subjects: 210
Study: 34039478

Group type: EXPERIMENTAL
Intervention: Aminoglycosides (amikacin and gentamicin) administered during CRRT.
Number of subjects: 145

Group type: COMPARATOR
Intervention: Inappropriate reinjection threshold for gentamicin (>2 mg/L) and amikacin (>5 mg/L).
Number of subjects: 145
Study: 32196898

Group type: EXPERIMENTAL
Intervention: Outpatient oral treatment (cefixime)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Inpatient treatment (cefepime)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Outpatient group
Number of subjects: 117

Group type: COMPARATOR
Intervention: Inpatient group
Number of subjects: 117
Study: 35504178

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 32803560

Group type: EXPERIMENTAL
Intervention: Medication dispensing errors
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Prescription related errors
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Pharmacist counselling errors
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Wrong quantity errors
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Wrong drug errors
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Causes of errors
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Severity of errors
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Predictors of errors
Number of subjects: 350
Study: 34217774

Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 32439543

Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum (N2, N7) and Lactobacillus plantarum (N20)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lactobacillus strains
Number of subjects: 120
Study: 35176755

Group type: EXPERIMENTAL
Intervention: Tamoxifen (arm A, TAMOX/VOR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vorinostat (arm B, VOR)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tamoxifen and Vorinostat
Number of subjects: 31
Study: 33215533

Group type: COMPARATOR
Intervention: Commercial control soy formula (SF)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed SF (10% hydrolyzed)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 5% hydrolyzed SF
Number of subjects: 71
Study: 33173165

Group type: EXPERIMENTAL
Intervention: Bevacizumab added to standard adjuvant chemotherapy (FOFOX or XELOX)
Number of subjects: 3451

Group type: COMPARATOR
Intervention: Standard adjuvant chemotherapy (FOFOX or XELOX) without bevacizumab
Number of subjects: 3451
Study: 616120246

Group type: EXPERIMENTAL
Intervention: Triamcinolone Assisted Vitrectomy (VAT)
Number of subjects: 24
Study: 35228783

Group type: EXPERIMENTAL
Intervention: Cap. Torchnil & Tab. Febcin (Add-on Group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: SOC (SOC Group)
Number of subjects: 150
Study: 32958269

Group type: EXPERIMENTAL
Intervention: Water-only fasting for 24 hours before and 24 hours after each chemotherapy cycle
Number of subjects: 20
Study: 616063474

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB)
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB) after enrolment
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB) in TNBC
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB) in RAM arm
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB) after enrolment in RAM arm
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB) and treatment-emergent hypertension
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB) and treatment arm interaction
Number of subjects: 1144
Study: 34510652

Group type: EXPERIMENTAL
Intervention: Migraine (any migraine, migraine with aura, migraine without aura)
Number of subjects: 0
Study: 32593322

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor dapagliflozin
Number of subjects: 0
Study: 34028551

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cabazitaxel
Number of subjects: 0
Study: 33023132

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program (PREDIMED-Plus trial)
Number of subjects: 5695
Study: 34332617

Group type: EXPERIMENTAL
Intervention: ACLS + REBOA
Number of subjects: 200

Group type: COMPARATOR
Intervention: ACLS
Number of subjects: 200
Study: 32115111

Group type: EXPERIMENTAL
Intervention: Twin-block (TB) appliance
Number of subjects: 25

Group type: COMPARATOR
Intervention: sagittal-guidance Twin-block (SGTB) appliance
Number of subjects: 25
Study: 34226218

Group type: EXPERIMENTAL
Intervention: Microablative fractional radiofrequency (MAFRF) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaginal oestrogens
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 32573523

Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional cardiovascular rehabilitation (CCVR)
Number of subjects: 83
Study: 36495107

Group type: EXPERIMENTAL
Intervention: Sling exercises combined with targeted vibration and oscillations (SE + VO)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sling exercises (SE)
Number of subjects: 36
Study: 33955835

Group type: EXPERIMENTAL
Intervention: VR cognitive training (multidomain and neuropsychologist-assisted) in a fully immersive VR environment, twice a week for 1 month
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: VR cognitive training
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (usual therapy such as pharmacotherapy)
Number of subjects: 41
Study: 32602000

Group type: EXPERIMENTAL
Intervention: Combination method using CEUS and blue dye (BD)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Single blue dye (BD) method
Number of subjects: 134
Study: 34159732

Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) with 10 mL of 0.375% ropivacaine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Local anesthesia (LA) with subcutaneous and fascial injection of 10 mL of 0.75% ropivacaine
Number of subjects: 62
Study: 34790535

Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE)
Number of subjects: 234
Study: 33152308

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy after chemoradiotherapy
Number of subjects: 0
Study: 35000693

Group type: EXPERIMENTAL
Intervention: Adaptive Goal Setting
Number of subjects: 512

Group type: COMPARATOR
Intervention: Static Goal Setting
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Immediate Reinforcement
Number of subjects: 512

Group type: COMPARATOR
Intervention: Delayed Reinforcement
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Adaptive Goals + Immediate Reinforcement
Number of subjects: 512

Group type: COMPARATOR
Intervention: Static Reinforcement
Number of subjects: 512
Study: 32179241

Group type: EXPERIMENTAL
Intervention: Anthocyanins 320 mg/day
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Anthocyanins 40 mg/day
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Anthocyanins 80 mg/day
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Anthocyanins (all doses)
Number of subjects: 169
Study: 35653981

Group type: EXPERIMENTAL
Intervention: Encorafenib plus cetuximab with binimetinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Encorafenib plus cetuximab without binimetinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (irinotecan plus cetuximab or FOLFIRI plus cetuximab)
Number of subjects: 0
Study: 33603778

Group type: EXPERIMENTAL
Intervention: Lower limb CIMT with 600 repetitions (group 1)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Lower limb CIMT with 3 hours of task practice (group 2)
Number of subjects: 58
Study: 32041913

Group type: EXPERIMENTAL
Intervention: Ciplukan extract 3 x 250 mg/day for 12 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 36039973

Group type: EXPERIMENTAL
Intervention: Flexion-based exercises
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Extension-based exercises
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 34425791

Group type: EXPERIMENTAL
Intervention: Capitation model of care
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Capitation payment formula
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Systematic reflection methodology
Number of subjects: 950
Study: 34048330

Group type: EXPERIMENTAL
Intervention: Mobile phone accessibility features
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Comparative analysis by disability type and phone type
Number of subjects: 570
Study: 33254048

Group type: EXPERIMENTAL
Intervention: Positive pictures
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Negative pictures
Number of subjects: 178

Group type: COMPARATOR
Intervention: Exposure only condition (looking at a cross)
Number of subjects: 178
Study: 34639282

Group type: EXPERIMENTAL
Intervention: IBCT-based conflict prevention program (5 sessions of 120 minutes each)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 6
Study: 36181377

Group type: EXPERIMENTAL
Intervention: Sugammadex (8 mg∙kg−1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg∙kg−1 and 4 mg∙kg−1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neostigmine (0.03 mg∙kg−1)
Number of subjects: 40